Strides Pharma Science Ltd - 532531 - Reg. 34 (1) Annual Report.
Annual Report for FY2021-2218-08-2022
18-08-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules18-08-2022
Strides Pharma Science Ltd - 532531 - Notice Of The 31St Annual General Meeting And Annual Report For FY 2021-22
This is to inform you that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 9, 2022, at 12:30 hrs IST through Video Conference/ Other Audio-Visual Means. As required under SEBI Listing Regulations, we are enclosing herewith Notice of the AGM and Annual Report for FY 2021-22 which is being sent through electronic mode to the Members of the Company. A copy of the same is also available on the Company's website www.strides.com This is for your information and records.18-08-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement titled 'Intimation about 31st Annual General Meeting of the Company.''17-08-2022
Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August 09, 2022 for S Vimalkumar10-08-2022
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 09, 2022 for Vimal Kumar S10-08-2022
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 09, 2022 for Pronomz Ventures LLP09-08-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides announces successful completion of US FDA inspection at its Singapore facility08-08-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find enclosed herewith transcript of the Earnings Call held on July 29, 2022.04-08-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Cyclosporine Softgel Capsules03-08-2022